Back to results
US 6,737,259 B1Granted
Modified arginine deiminase
AssigneePhoenix Pharmacologics, Inc.
InventorMike A. Clark
Life of this patent
Estimating the term…
Abstract
The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
Claims14
A compound comprising arginine deiminase covalently bonded via a linking group to polyethylene glycol,
- wherein the arginine deiminase is obtained from a microorganism selected from the group consisting of Streptococcus pyogenes, Streptococcus pneumoniae, Borrelia burgdorferi, Borrelia afzelii, Giardia intestinalis, Clostridium perfringens, Enterococcus faecalis, Lactobacillus sake, Bacillus licheniformis, and combinations thereof;
- wherein the polyethylene glycol has a total weight average molecular weight of from about 1,000 to about 40,000, and
- wherein the linking group is selected from the group consisting of a succinimide group, an amide group, an imde group, a carbamate group, an ester group, an epoxy group, a carboxyl group, a hydroxyl group, a carbohydrate, a tyrosine group, a cysteine group, a histidine group and combinations thereof.
Dependencies are inferred from the claim text.